Astellas Pharma

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company headquartered in Tokyo. It was created on 1 April 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, two established Japanese drugmakers with roots extending back to the late nineteenth and early twentieth centuries. The merger combined Yamanouchi's strengths in prescription medicines and international commercial operations with Fujisawa's research capabilities and overseas presence, creating a company with a substantially broader global platform. The company's business is centered on innovative prescription medicines. Its historically important therapeutic franchises have included urology, transplantation and immunology, oncology, infectious disease, cardiology, and selected specialty-care markets. Astellas has developed and commercialized medicines both independently and through partnerships, frequently working with companies such as Pfizer, Gilead Sciences, Roche and Theravance. Its products have included treatments for prostate and bladder cancers, organ-transplant rejection, overactive bladder, fungal infections, anemia associated with chronic kidney disease, menopause-related vasomotor symptoms, and other conditions. Among the company's best-known products are Xtandi, an androgen-receptor inhibitor for prostate cancer commercialized with Pfizer; Prograf and related tacrolimus products for prevention of organ-transplant rejection; Vesicare and Myrbetriq for overactive bladder; Xospata for certain acute myeloid leukemia cases; Padcev for bladder cancer; Cresemba and Mycamine for serious fungal infections; and Veozah for menopause-related hot flashes. Product rights, labels, geographic availability and marketing arrangements vary by jurisdiction, and some older products continue to carry legacy brand identities from the predecessor companies or earlier commercial partnerships. Astellas has pursued growth through internal discovery, licensing, collaborations and acquisitions. Major transactions have expanded its oncology, regenerative medicine, genetic regulation, cell therapy, neuromuscular and ophthalmology capabilities. Notable deals include the 2010 acquisition of OSI Pharmaceuticals, the 2015 purchase of Ocata Therapeutics, the 2016 acquisition of Ganymed Pharmaceuticals, the 2019 acquisition of Audentes Therapeutics and Xyphos Biosciences, and the 2023 acquisition of Iveric Bio. The company has also acquired or partnered with smaller biotechnology businesses to strengthen its pipeline in areas such as women's health, rare disease, gene therapy and age-related disease. The company operates research and development facilities in Japan, North America and Europe, while clinical-development activities have been associated with locations including Northbrook and La Jolla in the United States and Leiden in the Netherlands. Its public identity emphasizes research-led innovation and the ability to improve patients' lives. Astellas has used the English slogan "Leading Light for Life" and the Japanese expression "Ashita wa kaerareru," commonly rendered as "Changing Tomorrow." It remains an active, publicly listed pharmaceutical group with a global commercial and research footprint.

Astellas's corporate history combines the development of Fujisawa Pharmaceutical and Yamanouchi Pharmaceutical. Fujisawa Shoten was established in Osaka in 1894 by Tomokichi Fujisawa and adopted the Fujisawa Pharmaceutical name in 1943. Yamanouchi Yakuhin Shokai was founded in Osaka in 1923 by Kenji Yamanouchi; it became Yamanouchi Pharmaceutical in 1940 and relocated to Tokyo in 1942. Both predecessor companies built international operations during the postwar expansion of the Japanese pharmaceutical industry. Fujisawa opened an office in Taiwan in 1962, while Yamanouchi established a Taiwan presence in 1963. Both later developed operations in the United States and Europe from the late 1970s onward. Their internationalization provided the commercial and regulatory infrastructure that later supported Astellas's global business. Fujisawa expanded through acquisitions, including the 1990 purchase of Lyphomed, which helped establish a U.S. research center in Deerfield, Illinois. Yamanouchi strengthened European research through its 1991 acquisition of the pharmaceutical division of Royal Gist Brocades and established a research center in Leiderdorp in the Netherlands. These moves contributed to the scientific and geographic capabilities that the merged company inherited. The two companies completed a merger of equals on 1 April 2005, creating Astellas Pharma. The new company initially combined the predecessor organizations' commercial portfolios and research programs, while some established products continued to use legacy names because of their recognition among physicians and patients. Astellas subsequently pursued a strategy based on selected therapeutic areas, internal research, external innovation and business development. A major step in this strategy was the 2010 acquisition of OSI Pharmaceuticals, which strengthened oncology and added a substantial U.S. research and commercial presence. During the following decade Astellas expanded its partnership and acquisition activity across regenerative medicine, oncology, women's health, rare disease, neuromuscular conditions, gene therapy and ophthalmology. Transactions involving Ocata, Ganymed, Ogeda, Mitobridge, Quethera, Potenza, Audentes, Xyphos, iota Biosciences and Iveric Bio illustrate the company's effort to supplement its traditional small-molecule portfolio with biologics, cell therapies, genetic regulation technologies and specialty medicines. The company has also reshaped its portfolio through divestitures and product transfers. In 2015 it agreed to sell its dermatology business to LEO Pharma, and in 2017 it transferred a group of medicines to LTL Pharma. In the United Kingdom, distribution arrangements for Prograf and Advagraf were adjusted after complaints about product availability, moving from a narrower arrangement to a structure involving multiple wholesalers. Astellas's modern business has been organized around franchises including oncology, urology, immunology and transplantation, cardiology and infectious disease, with research priorities also extending to areas such as diabetes, gastrointestinal disorders and central nervous system diseases. Research infrastructure has included sites in Japan, the United States and Europe, while clinical development has been conducted through international networks. The company remains a publicly listed Japanese pharmaceutical group with worldwide operations.

1. 2023Iveric Bio acquisition announced

   Astellas announced the acquisition of Iveric Bio to expand its ophthalmology business.

   Source
2. 2019Audentes and Xyphos added

   Astellas announced the Audentes acquisition and acquired Xyphos Biosciences, adding gene-therapy and engineered-cell-control capabilities.

   Source
3. 2015Ocata acquisition announced

   Astellas announced its purchase of Ocata Therapeutics to expand regenerative medicine.

   Source
4. 2010OSI Pharmaceuticals acquired

   Astellas completed its acquisition of OSI Pharmaceuticals, reinforcing oncology.

   Source
5. 2005Astellas Pharma formed

   Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical merged on 1 April 2005.

   Source
6. 1990Fujisawa acquires Lyphomed

   The acquisition supported Fujisawa's U.S. research and operating platform.

   Source
7. 1923Yamanouchi predecessor founded

   Kenji Yamanouchi founded Yamanouchi Yakuhin Shokai in Osaka.

   Source
8. 1894Fujisawa predecessor founded

   Tomokichi Fujisawa established Fujisawa Shoten in Osaka, creating the predecessor of Fujisawa Pharmaceutical.

   Source

A global research-based pharmaceutical company focused on innovative prescription medicines and specialty-care therapies.

• XtandiOncology

  Enzalutamide, an androgen-receptor signaling inhibitor used in the treatment of prostate cancer. The product is commercialized through a collaboration with Pfizer and is one of Astellas's most prominent oncology brands.

• Prograf and AdvagrafTransplantation and immunology

  Tacrolimus-based products used to help prevent rejection after organ transplantation. The products have been marketed in different formulations and regions, with packaging and labeling changes made after European dosing-error concerns.

• VesicareUrology

  Solifenacin succinate, a treatment for overactive bladder symptoms. Vesicare is one of the legacy products associated with Astellas's longstanding urology franchise.

• MyrbetriqUrology

  Mirabegron, a medicine for overactive bladder. Brand ownership and commercialization arrangements differ by market; Astellas has marketed it in the United States while Pfizer has marketed it in certain other territories.

• PadcevOncology

  Enfortumab vedotin, an antibody-drug conjugate used in bladder-cancer treatment. It represents Astellas's focus on targeted oncology therapies and is commercialized through collaboration.

• XospataOncology

  Gilteritinib, a targeted oncology medicine associated with treatment of certain acute myeloid leukemia cases involving specific molecular abnormalities.

• CresembaAnti-infective

  Isavuconazole, an antifungal medicine used for serious invasive fungal infections. It is part of Astellas's anti-infective portfolio and has been commercialized through regional arrangements.

• VeozahWomen's health

  Fezolinetant, a nonhormonal treatment for menopause-related vasomotor symptoms such as hot flashes. The product originated from the Ogeda acquisition and broadened Astellas's specialty-care presence.

• MycamineAnti-infective

  Micafungin sodium, an echinocandin antifungal used against serious fungal infections.

• ProtopicImmunology and dermatology

  Tacrolimus ointment used in the management of atopic dermatitis and related eczema conditions.

• Leading Light for Life

  International

  Astellas's English corporate slogan, expressing its positioning around scientific innovation and improving patients' lives.

  Source
• Changing Tomorrow

  Japan

  The Japanese corporate expression "Ashita wa kaerareru" presents the company as working to change future health outcomes through medicines and research.

  Source

• 2023Acquisition of Iveric BioM&A

  Astellas pursued expansion in ophthalmology and retinal disease.

  What changed. The company announced an agreement to acquire Iveric Bio for approximately $5.9 billion.

  Aftermath. The transaction strengthened Astellas's ophthalmology portfolio and late-stage specialty pipeline.

  Transaction value. Approximately $5.9 billion (2023)

  Source
• 2019Acquisition of Audentes TherapeuticsM&A

  Astellas wanted to build a substantial genetic-regulation and gene-therapy business.

  What changed. Astellas agreed to acquire Audentes for approximately $3 billion in cash and planned to operate it as a wholly owned center of excellence.

  Aftermath. Audentes became part of Astellas's genetic-regulation activities, while the transaction also brought manufacturing and development capabilities for AAV programs.

  Transaction value. Approximately $3 billion (2019)

  Source
• 2015Acquisition of Ocata TherapeuticsM&A

  Astellas sought to broaden its capabilities in regenerative medicine.

  What changed. The company announced the acquisition of Ocata Therapeutics, formerly Advanced Cell Technology.

  Aftermath. The transaction was completed in February 2016 and added a regenerative-medicine platform.

  Source
• 2010Acquisition of OSI PharmaceuticalsM&A

  Astellas aimed to strengthen its oncology business and U.S. research platform.

  What changed. Astellas acquired OSI Pharmaceuticals in a transaction reported at approximately $4 billion.

  Aftermath. The deal expanded Astellas's oncology capabilities and presence in the United States.

  Transaction value. $4 billion (2010)

  Source
• 2005Merger of Yamanouchi and FujisawaM&A

  The two companies sought to combine their Japanese and international pharmaceutical businesses.

  What changed. They completed a merger of equals and began operating as Astellas Pharma on 1 April 2005.

  Aftermath. The transaction created a global pharmaceutical group with combined research, commercial and international capabilities.

  Source

• 2023Employee detention in ChinaControversy

  Astellas reported that an employee had been detained by Chinese authorities on alleged espionage grounds. The Japanese government criticized the detention as arbitrary.

  Source
• 2019Medicare copay-foundation settlementControversy

  Astellas agreed to pay $100 million to resolve U.S. Department of Justice allegations that it had conspired to provide improper kickbacks through Medicare copay foundations.

  Source
• 2018Research-funding and clinical-protocol reprimandControversy

  The Prescription Medicines Code of Practice Authority reported concerns about research funding awarded to a senior clinician and about Astellas's failure to provide investigators with sufficient and timely information after a hospital protocol was later abandoned.

  Source
• 2017Suspension extended over oversight and promotional-material findingsControversy

  The industry suspension was extended after findings concerning nurse oversight and training and incomplete prescribing information. Astellas was also reprimanded over promotional materials for several medicines that lacked required safety information.

  Source
• 2016United Kingdom industry-code suspensionControversy

  The Association of the British Pharmaceutical Industry suspended Astellas for a year after findings that the company had not fully disclosed the nature of a meeting described as an advisory board and had misled the relevant medicines-code authority.

  Source
• 2009Tacrolimus packaging and labeling concerns in EuropeControversy

  Prograf and Advagraf were reported to be susceptible to dosing errors in Europe, with serious adverse reactions reported among some patients. Packaging and labeling were subsequently corrected following a warning from the United Kingdom medicines regulator.

  Source

• 2023Astellas announces acquisition of Iveric Bio

  Astellas announced a transaction valued at approximately $5.9 billion to acquire Iveric Bio and strengthen its ophthalmology portfolio.

  M&A
  Source
• 2020Astellas acquires iota Biosciences

  The acquisition expanded Astellas's work in bioelectronic medicine and related technology platforms.

  M&A
  Source
• 2019Astellas acquires Audentes Therapeutics

  Astellas announced a roughly $3 billion cash acquisition of Audentes, expanding its gene-therapy and genetic-regulation platform.

  M&A
  Source
• 2017Astellas acquires Ogeda

  Astellas agreed to acquire Belgian drug-discovery company Ogeda, including the late-stage fezolinetant program.

  M&A
  Source
• 2016Astellas acquires Ganymed Pharmaceuticals

  The acquisition added Ganymed's oncology research and antibody-development assets to Astellas.

  M&A
  Source
• 2015Astellas acquires Ocata Therapeutics

  Astellas announced the purchase of Ocata Therapeutics, formerly Advanced Cell Technology, to expand its regenerative-medicine capabilities.

  M&A
  Source
• 2015Astellas sells dermatology business to LEO Pharma

  The company agreed to divest its dermatology business to LEO Pharma as part of portfolio management.

  M&A
  Source
• 2014Astellas expands collaboration with Cytokinetics

  The companies broadened research and commercialization work on skeletal-muscle activators, including development of CK-2127107.

  Other
  Source
• 2010Astellas acquires OSI Pharmaceuticals

  Astellas announced and completed the acquisition of OSI Pharmaceuticals in a transaction valued at approximately $4 billion, strengthening its oncology portfolio.

  M&A
  Source
• 2005Astellas completes formation through merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical

  The two Japanese pharmaceutical companies combined on 1 April 2005 to form Astellas Pharma.

  M&A
  Source

1. Astellas Pharma
2. Astellas Pharma official website